Medicus Pharma Files Optimized Seamless Phase 2b/3 Registration-Intent Protocol To FDA For Teverelix To Treat Advanced Prostate Cancer
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today announced
Medicus Pharma asked the FDA to approve a new prostate cancer medicine. This is a big step forward, so watch if the company hits its testing goals.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.